Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.

@article{Harris2001InductionOT,
  title={Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.},
  author={Lyndsay N. Harris and Lu Yang and Vlayka B Liotcheva and Sergio Pauli and James Dirk Iglehart and O. Michael Colvin and Tao-shih Hsieh},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2001},
  volume={7 6},
  pages={
          1497-504
        }
}
ErbB2 (HER-2) gene amplification and overexpression have been shown to predict a better outcome with doxorubicin-based chemotherapy as opposed to alkylator-based chemotherapy in early stage breast cancer. To understand the mechanism of differential response to these two regimens, we have evaluated the effect of signaling through the ErbB2 receptor on downstream enzymes that may affect drug response, using two different models. The first system employs breast cancer cells that have high levels… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 36 CITATIONS, ESTIMATED 51% COVERAGE

71 Citations

0510'02'05'09'13'17
Citations per Year
Semantic Scholar estimates that this publication has 71 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 34 REFERENCES

Induction of chemotherapy sensitivity in MCF-7 breast cancer cells by heregulin

  • L. Harris, C. Tang, C. Yang, A. Harris, R. Lupu
  • Clin. Cancer Res.,
  • 1998
Highly Influential
3 Excerpts

Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/ neu overexpression

  • G. Konecy, M. D. Pegram, M. Beryt, M. Untch, D. J. Slamon
  • Proc. BCRT,
  • 1999
1 Excerpt

Similar Papers

Loading similar papers…